Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
1991-7-17
|
| pubmed:abstractText |
Forty-eight patients with advanced testicular cancer, defined as abdominal mass greater than 10 cm, mediastinal mass greater than 5 cm, more than 20 lung metastases, or visceral organ involvement were treated with an intensive, alternating five-drug regimen consisting of cisplatin 50 mg/m2 d 1-3, etoposide 170 mg/m2 d 1-3, ifosfamide 5 g/m2 d 15, vincristine 2 mg weekly, bleomycin 15 mg/m2 weekly, q d 28. Thirty-four (71%) of the patients attained tumor-free status. This was achieved by chemotherapy alone in 14 patients and by surgical resection of residual disease in the remaining 20 patients (histology of resected tissue: necrosis 12, mature teratoma 7, viable carcinoma 1). Patients with pure seminoma responded better than patients with nonseminoma (CR 100% vs. 67%, respectively). In a univariate analysis only the value of HCG (less than vs greater than 10,000 U/L) and the number of involved organ sites (less than or equal to 2 vs greater than to 2) had significant influence on the response rate. After a minimum follow-up of 24 months 3 patients (9%) have relapsed. The survival rate is 76% after 36 months, with 61% remaining disease-free. Though this intensive regimen might bestow some of the therapeutic advantages of standard three-drug protocols in far advanced testicular cancer, the results are still less than optimal and warrant the exploration of new therapeutic strategies.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
0923-7534
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
2
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
197-202
|
| pubmed:dateRevised |
2006-4-24
|
| pubmed:meshHeading |
pubmed-meshheading:1710481-Adolescent,
pubmed-meshheading:1710481-Adult,
pubmed-meshheading:1710481-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:1710481-Bleomycin,
pubmed-meshheading:1710481-Cisplatin,
pubmed-meshheading:1710481-Combined Modality Therapy,
pubmed-meshheading:1710481-Dysgerminoma,
pubmed-meshheading:1710481-Follow-Up Studies,
pubmed-meshheading:1710481-Humans,
pubmed-meshheading:1710481-Ifosfamide,
pubmed-meshheading:1710481-Male,
pubmed-meshheading:1710481-Middle Aged,
pubmed-meshheading:1710481-Neoplasms, Germ Cell and Embryonal,
pubmed-meshheading:1710481-Remission Induction,
pubmed-meshheading:1710481-Survival Analysis,
pubmed-meshheading:1710481-Testicular Neoplasms,
pubmed-meshheading:1710481-Vincristine
|
| pubmed:year |
1991
|
| pubmed:articleTitle |
Cisplatin, etoposide, ifosfamide, vincristine and bleomycin combination chemotherapy for far advanced testicular carcinoma.
|
| pubmed:affiliation |
University of Hannover, Germany.
|
| pubmed:publicationType |
Journal Article
|